Skip to main navigation
Skip to search
Skip to main content
Research Profiles at Washington University School of Medicine Home
Help & FAQ
Home
Profiles
Departments, Divisions and Centers
Research output
Search by expertise, name or affiliation
Inflammatory demyelinating neuropathies
Glenn Lopate,
Alan Pestronk
Institute of Clinical and Translational Sciences (ICTS)
Section of Neuromuscular Medicine
Hope Center for Neurological Disorders
Research output
:
Contribution to journal
›
Review article
›
peer-review
9
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Inflammatory demyelinating neuropathies'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Activities of Daily Living
14%
Adverse Effects
14%
Age-related Risk
14%
Anti-glycolipid Antibody
14%
Anti-GM1
14%
Autonomic Instability
14%
Bulbar
14%
Cardiac Disease
14%
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
28%
Chronic Treatment
14%
Controlled Comparison
14%
Corticosteroids
71%
Demyelinating Neuropathy
100%
Disease Severity
14%
Drug Choice
14%
Enhanced Strength
14%
Every Other Day
14%
Functional Capacity
14%
Gait Disorders
14%
Good Safety
14%
GQ1b
14%
Guillain-Barré Syndrome
28%
Hemodynamic Instability
14%
Hepatic Disease
14%
High Dose
14%
Human Immune System
100%
Illness
14%
Immune Globulin
100%
Immune Plasma
14%
Immunomodulatory Therapy
14%
Immunosuppressive Agents
14%
Initial Treatment
14%
Intensive Care Unit
14%
Methylprednisolone
14%
Mild Symptoms
14%
Moderate to Severe
14%
Multicenter Randomized Controlled Trial
14%
Patient Response
14%
Plasma Exchange
71%
Potential Drug Interactions
14%
Respiratory muscle Strength
14%
Safety Profile
14%
Second-line Agents
14%
Sensory Loss
14%
Severe Symptoms
14%
Side Effect Profile
14%
Strength Abilities
14%
Supportive Care
14%
Therapy Choice
28%
Therapy Experiences
14%
Therapy Goals
28%
Treatment Costs
14%
Venous Access
28%
Medicine and Dentistry
Activities of Daily Living
14%
Adverse Effect
14%
Antiserum
14%
Comparison Trial
14%
Contraindication
28%
Demyelinating Neuropathy
100%
Deterioration
14%
Disease Severity
14%
Diseases
14%
Drug Interaction
14%
Drug Megadose
14%
Gait Disorder
14%
Health Care Cost
28%
Heart Disease
14%
Hemodynamic
14%
Human Immunoglobulin
100%
Immunomodulating Agent
14%
Intensive Care Unit
14%
Liver Disease
14%
Methylprednisolone
14%
Mouth
14%
Plasma Exchange
71%
Polyradiculoneuropathy
28%
Randomized Controlled Trial
14%
Side Effect
14%
Supportive Care
14%
Weakness
14%
Pharmacology, Toxicology and Pharmaceutical Science
Antiserum
14%
Comparison Trial
14%
Demyelinating Neuropathy
100%
Deterioration
14%
Disease Severity
14%
Diseases
14%
Drug Interaction
14%
Gait Disorder
14%
Heart Disease
14%
Human Immunoglobulin
100%
Immunomodulating Agent
14%
Liver Disease
14%
Methylprednisolone
14%
Polyradiculoneuropathy
28%
Randomized Controlled Trial
14%
Side Effect
14%
Syndrome
28%
Weakness
14%